Grossman Adam S's Form 4 filing
Adma Biologics, Inc.ADMA · filed Aug 18, 2023
- Accession no.
- 0001140361-23-040583
- Filed
- Aug 18, 2023
- Trade date
- Aug 18, 2023
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $1.04M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Grossman Adam SCIK 0001542517 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2023 | Common Stock | SSaleDisposed | −250,000 | $4.15F1 | −$1,037,500 | 2,273,085 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reflects the weighted average price of sales on August 18, 2023. The shares were sold in multiple transactions at prices ranging from $4.09 to $4.255, inclusive.
Referenced by the price of 1 transaction in Table I.